R&D >

BNS-Doxorubicin

HOME > R&D > BNS-Doxorubicin

Χ
Under construction please wait.
BNS-Doxorubicin: 3rd generation Doxorubicin
  • 1st Generation
    • Doxorubin HCl
    • Developed in 1960's
    • Used for diverse cancer
      treatment
  • 2nd Generation
    • Liposomal doxorubicin HCl
    • US FDA approval in 1995
    • No active targeting to tumor
    • Indication: breast ca.,
      ovarian ca., multiple
      myeloma, AIDS related
      Kaposi's sarcoma
  • 3rd Generation
    • BNS-doxorubicin
    • Active targeting to tumor
    • Mechanism: tumor
      endothelial cell destruction